Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + tislelizumab + raltitrexed + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Guangdong Provincial People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Hepatic Arterial Infusion
01
Overview
This investigational combination therapy is being evaluated for the treatment of advanced hepatocellular carcinoma (HCC). It consists of four active agents: lenvatinib, a multi-kinase inhibitor targeting VEGFR, FGFR, PDGFRα, RET, and KIT; tislelizumab, a humanized IgG4 monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) receptor; and the RALOX regimen, which involves hepatic arterial infusion chemotherapy (HAIC) using raltitrexed (a thymidylate synthase inhibitor) and oxaliplatin (a platinum-based DNA cross-linking agent). This triple-modality approach (targeted therapy, immunotherapy, and locoregional chemotherapy) aims to improve outcomes in patients with unresectable or advanced HCC by combining systemic and direct-to-liver treatments. The regimen is currently being studied in a Phase II trial sponsored by Guangdong Provincial People's Hospital.
- Other names
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAICLenvatinib + Tislelizumab + RALOX-HAIC
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on lenvatinib + tislelizumab + raltitrexed + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + tislelizumab + raltitrexed + oxaliplatin.